Nemo-like kinase (NLK)

Nemo-like kinase is an evolutionarily conserved serine/threonine-protein kinase encoded by the *NLK* gene. It is considered an atypical member of the mitogen‑activated protein kinase family due to its divergent structure and activation mechanisms. Unlike typical MAPKs, it lacks dual phosphorylation motifs and is not activated by known MAP2 kinases. Instead, it can be activated through homodimerization followed by autophosphorylation. NLK regulates multiple key cellular processes by phosphorylating various transcription factors involved in cell fate decisions. It acts as a positive effector within non-canonical Wnt pathways while serving as a negative regulator within canonical Wnt/β-catenin signaling—by promoting dissociation/degradation of β-catenin-associated complexes—and also modulates Notch pathway activity. NLK has been implicated as a therapeutic target across several disease contexts. In cancer biology—particularly endocrine-resistant breast cancer—its overactivity supports tumor survival pathways; pharmacological inhibition with agents like VX‑702 shows promise preclinically. In hematology research on Diamond‑Blackfan anemia, suppression or modulation of NLK improves erythropoiesis outcomes. Additionally, dysregulation has been linked to neurodegenerative disorders. Given its broad regulatory roles—including impacts on immune cells—therapeutic targeting requires careful consideration due to potential safety concerns related to development and homeostasis disruption.

Other names

NLKSerine/threonine-protein kinase NLKProtein LAK1

– Inhibition of kinase activity to suppress survival signaling or pathological cell fate programs – Modulation through upstream kinases or microRNAs that regulate its expression/activity – Disruption of downstream phosphorylation events affecting transcription factor complexes and mTORC1 localization/functionality